Technical Analysis for PBYI - Puma Biotechnology Inc
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
50 DMA Resistance | Bearish | -5.87% | |
Fell Below 20 DMA | Bearish | -5.87% | |
Bollinger Band Squeeze | Range Contraction | -5.87% | |
Crossed Above 20 DMA | Bullish | -9.44% | |
MACD Bullish Signal Line Cross | Bullish | -9.44% | |
Bollinger Band Squeeze | Range Contraction | -9.44% | |
Bollinger Band Squeeze | Range Contraction | -3.33% | |
180 Bearish Setup | Bearish Swing Setup | -2.92% |
Alert | Time |
---|---|
Down 3% | about 23 hours ago |
60 Minute Opening Range Breakdown | about 23 hours ago |
10 DMA Support | about 23 hours ago |
Down 2 % | about 23 hours ago |
Fell Below Previous Day's Low | about 23 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 06/18/2024
Puma Biotechnology Inc Description
Puma Biotechnology, Inc., a development stage biopharmaceutical company, engages in the acquisition, development, and licensing of products for the treatment of various forms of cancer. Its drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients and non-small cell lung cancer patients; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also involved in developing PB357, an orally administered agent, which is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Organic Compounds Breast Cancer Chemical Compounds Non Small Cell Lung Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Protein Kinase Inhibitor Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Signal Transduction Tyrosine Kinase Her2 Chloroarenes Her2/Neu Pyridines Advanced Breast Cancer Advanced Cancer Nitriles
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 7.73 |
52 Week Low | 2.13 |
Average Volume | 432,603 |
200-Day Moving Average | 4.27 |
50-Day Moving Average | 5.17 |
20-Day Moving Average | 4.92 |
10-Day Moving Average | 4.83 |
Average True Range | 0.31 |
RSI (14) | 40.48 |
ADX | 10.7 |
+DI | 21.12 |
-DI | 25.00 |
Chandelier Exit (Long, 3 ATRs) | 4.50 |
Chandelier Exit (Short, 3 ATRs) | 5.28 |
Upper Bollinger Bands | 5.22 |
Lower Bollinger Band | 4.62 |
Percent B (%b) | 0.05 |
BandWidth | 12.24 |
MACD Line | -0.12 |
MACD Signal Line | -0.13 |
MACD Histogram | 0.0072 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 5.24 | ||||
Resistance 3 (R3) | 5.30 | 5.17 | 5.14 | ||
Resistance 2 (R2) | 5.17 | 5.02 | 5.14 | 5.10 | |
Resistance 1 (R1) | 4.91 | 4.93 | 4.85 | 4.85 | 5.07 |
Pivot Point | 4.78 | 4.78 | 4.75 | 4.75 | 4.78 |
Support 1 (S1) | 4.52 | 4.63 | 4.46 | 4.46 | 4.23 |
Support 2 (S2) | 4.39 | 4.54 | 4.36 | 4.20 | |
Support 3 (S3) | 4.13 | 4.39 | 4.16 | ||
Support 4 (S4) | 4.07 |